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a  b  s  t  r  a  c  t
Canine  osteosarcoma  is the  most  common  bone  cancer,  and  an important  cause  of mortality  and  mor-
bidity,  in  large  purebred  dogs.  Previously  we  constructed  two  multivariable  models  to  predict  a  dog’s
5-month  or  1-year  mortality  risk  after  surgical  treatment  for osteosarcoma.  According  to  the  5-month
model,  dogs  with a relatively  low  risk  of  5-month  mortality  beneﬁted  most  from  additional  chemother-
apy  treatment.  In the  present  study,  we  externally  validated  these  results  using  an  independent  cohort
study  of 794  dogs. External  performance  of  our  prediction  models  showed  some  disagreement  between
observed  and  predicted  risk,  mean  difference:  −0.11 (95%  conﬁdence  interval  [95%  CI]-0.29; 0.08)  for  5-
month  risk  and  0.25  (95%CI  0.10;  0.40)  for 1-year  mortality  risk.  After  updating  the  intercept,  agreement
improved:  −0.0004  (95%CI-0.16;  0.16)  and  −0.002  (95%CI-0.15;  0.15).  The  chemotherapy  by  predicted
mortality  risk  interaction  (P-value  =  0.01)  showed  that the chemotherapy  compared  to  no  chemother-ersonalized medicine
ncology
one tumor
apy  effectiveness  was  modiﬁed  by 5-month  mortality  risk:  dogs  with  a relatively  lower  risk  of  mortality
beneﬁted  most  from  additional  chemotherapy.  Chemotherapy  effectiveness  on  1-year  mortality  was  not
signiﬁcantly  modiﬁed  by  predicted  risk  (P-value  =  0.28).  In conclusion,  this  external  validation  study  con-
ﬁrmed  that  our  multivariable  risk  prediction  models  can  predict  a patient’s  mortality  risk  and  that  dogs
with  a relatively  lower  risk  of 5-month  mortality  seem  to  beneﬁt  most  from  chemotherapy.
© 2016  Elsevier  B.V.  All  rights  reserved.. Introduction
Surgically treated dogs with appendicular osteosarcoma (OS),
 malignant tumor of mesenchymal origin that produces osteoid,
ave a median survival time of 5 months (Brodey and Abt, 1976;
ooley and Waters, 1997; McNeill et al., 2007; Norrdin et al., 1989;
u et al., 1998; Spodnick et al., 1992; Straw and Withrow, 1996). For
he average patient, previous studies have shown that additional
∗ Corresponding author at: Farr Institute of Health Informatics Research, Uni-
ersity College London, 222 Euston Road, Room 206, London NW1  2DA, United
ingdom.
E-mail address: amand.schmidt@ucl.ac.uk (A.F. Schmidt).
1 Current address: Hills Pet Nutrition, 400 SW 8th Ave, Topeka, KS 66603, USA.
ttp://dx.doi.org/10.1016/j.prevetmed.2016.01.004
167-5877/© 2016 Elsevier B.V. All rights reserved.chemotherapy can extend median survival beyond these 5 months
(Bailey et al., 2003; Chun et al., 2000, 2005; Straw et al., 1991; Vail
et al., 2002).
Recently, using an Individual Patient Data Meta-Analysis
(IPDMA), we constructed a multivariable prediction tool, predict-
ing a dog’s risk of mortality at 5 months and 1 year after receiving
surgical treatment for OS (Schmidt et al., 2013). This tool predicts
mortality risk based on a patient’s age, weight, gender, neuter sta-
tus, serum alkaline phosphatase (SALP) level, breed, and tumor
location. In a nested study, we  explored whether chemotherapy
effectiveness differed between dogs with a different predicted risk
(i.e., subgroup analysis; Schmidt et al., 2015). Results showed that
chemotherapy (compared to no chemotherapy) was most effec-
tive in dogs with a relatively low predicted risk. This implies that
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referentially treated with additional chemotherapy. Combining
nformation on a dog’s mortality risk with a personalized estimate
f treatment effect can aid veterinary professionals to better tailor
reatment to a dog’s needs, which is relevant in terms of extending
urvival, decreasing healthcare costs, and increasing quality of life.
In the present study, we validate these ﬁnding using an inde-
endent cohort study collected at the Flint Animal Cancer Center
t Colorado State University (Selmic et al., 2014). Speciﬁcally, we
rst applied our previously developed “original” prediction model
o these external data and determined model performance. Second,
e validated the differential chemotherapy effectiveness between
ogs with different baseline mortality risks.
. Materials and methods
The external validation of the prediction models and the
hemotherapy subgroup-speciﬁc effects were evaluated using a
ubset of the Colorado State University cohort study (Selmic et al.,
014); data were collected based on a retrospectively review of
lectronic medical records. For the current analyses, dogs were eli-
ible if they received surgical treatment (amputation or limb-spare)
or OS. Because of the relatively rare occurrence, 49 dog receiving
isplatin/carboplatin, cisplatin or any other kind of (combination)
hemotherapy were excluded. Patients were also excluded if they
eceived radiation therapy (n = 133), had a zero or negative follow-
p time (n = 15, measured from date of surgery to date of last
ontact), had an erroneous date of metastasis (after the date of
eath, n = 9), there was conﬁrmed or a suspicion of metastasis
t baseline (n = 16), received pamidronate (n = 9) or were small
urebred dogs (n = 5). Exclusion criteria were identical to our dis-
overy paper (Schmidt et al., 2015), with the slight difference
hat (to prevent small exposure categories) dogs with cisplatin or
oxorubicin combination therapy, or small pure bred dogs, were
xcluded. Data were collected based on medical records, hence
outine (scintigraphy based) staging information was not always
vailable. Additionally, we emphasize that sample size was deter-
ined in an opportunistic manner, without formal sample size
alculations; because of the retrospective nature of this cohort, this
id not impact patient safety.
For the 794 remaining patients, baseline data were available on
ge (years), weight (kg), gender (0 female, 1 male), neuter status (0
ntact, 1 neutered), high serum alkaline phosphatase (SALP) deﬁned
s above 140 IU/dL, continuous monocytes count (109cells/L), con-
inuous lymphocyte counts (109 cells/L), breed (0 other breed, 1
ottweiler, 2 Golden Retriever, 3 Labrador Retriever, 4 Greyhound,
 Doberman, 6 mixed breed) and tumor location (0 other, 1 prox-
mal humerus, 2 distal femur or proximal tibia, 3 distal radius).
dditionally, we recorded whether a dog received chemotherapy
0 no chemotherapy, 1 carboplatin or 2 doxorubicin) and if it was
live at 5 months and 1 year (0 alive, 1 dead).
On average, 11% percentage of these variables were missing, the
ercentage missingness per variable was: 1-year mortality 6.05%,
-month mortality 2.90%, chemotherapy 27.83%, age 0.13%, weight
.13%, gender 0.00%, neuter status 0.00%, high SALP 9.57%, mono-
ytes 18.89%, lymphocytes 18.89%, breed 0.00%, and tumor location
.39%. Univariable analyses showed that missingness was  depen-
ent on observed variables (available upon request) indicating that
 complete case analysis, excluding missing observations, would
e biased (Groenwold et al., 2012; Rubin, 1976). Instead, we used
he dependence between the missing observations and observed
ariables to impute missing values (Rubin, 1976) using the aregIm-
ute algorithm from the Hmisc package version 3.14-5 (Harrell and
upont, 2013). This algorithm was implemented using 5 burn-in
terations, predictive mean matching and 100 bootstrap samples
o determine the (non) linear relationship between the continuousry Medicine 125 (2016) 126–134 127
predictor variables and the missing values. To correct for the inher-
ent underestimation of the variance, 15 imputed datasets were
created (i.e., multiple imputation) (White and Carlin, 2010); results
of the 15 imputed datasets were pooled using Rubin’s rules (Little
and Rubin, 2002; Marshall et al., 2009).
2.1. Data analysis: prediction model validation
Based on the logistic regression version of our previous derived
prediction model (Schmidt et al., 2013), a patient’s 5-month and
1-year risk of mortality was calculated by summing the product
of their baseline variables and the relevant coefﬁcients (Table 1);
please note that because dogs with combination doxorubicin or
cisplatin therapy were excluded, the coefﬁcients for these therapies
become redundant. Formally, the predicted logit (mortality risk)
was calculated using Eq. (1):









Where i represent the ith individual and j the jth variable presented
in Table 1, ˆˇ js the natural logarithm of the odds ratio for 5-month
mortality and x the variable status after surgical treatment. The
predicted logit(1-year mortality risk) was estimated by replacing
ˆˇ
j by ˆj . Finally, the mortality risk was  calculated by taking the
inverse of the predicted logit (mortality risk), Table 1. Note that
for ease of notation, we  will often drop the “predicted” from logit
(mortality risk), however unless stated otherwise this always refers
to an estimate from Eq. (1).
Obviously, these calculations are only relevant for future
patients if we can assume the model to be correctly speci-
ﬁed (i.e., describe the relationship between the predictors and
outcome sufﬁciently). To evaluate the models predictive perfor-
mance in this independent validation study we calculated the
c-statistic, calibration slope and calibration-in-the-large (Harrell
et al., 1996). Calibration was also graphically assessed by plot-
ting the mean observed risk per deciles on the y-axis and the
predicted risk on the x-axis (i.e., a graphical representation of
the Hosmer–Lemeshow goodness-of-ﬁt test) (Harrell et al., 1996;
Steyerberg, 2009; Steyerberg et al., 2010). Please, see Appendix A
of Supplementary material for a description of the metrics inter-
pretability.
Besides this simple external validation, the prediction models
were corrected for any systematic difference between observed and
predicted risk (i.e., calibration-in-the-large /= 0) by re-estimating
the intercept in “Update 1” (Moons et al., 2012; Steyerberg, 2009).
Such recalibartion can be readily applied in clinical practice using
a relatively small number of events (e.g., 30) (Steyerberg, 2009). To
aid clinicians in updating the model to their local setting computer
code is provided in Appendix A of Supplementary material.
2.1.1. Data analysis: estimating chemotherapy effectiveness
After determining the external performance of our predic-
tion models (predicting 5-month and 1-year mortality risk), we
assessed whether the effect of “any chemotherapy” (carboplatin
or doxorubicin) compared to no chemotherapy in preventing mor-
tality differed between patients with different predicted risks of
mortality. To explore consistency, all analyses are repeated for car-
boplatin compared to no chemotherapy and doxorubicin compared
to no chemotherapy at 5-month and 1-year mortality.
This approach to tailor chemotherapy effects was previously
described in detail in Schmidt et al. (2015), which we  brieﬂy
repeat here. To get an estimate of the risk of mortality if the
patient remained untreated with chemotherapy, we re-calculated
the logit (mortality risk) by setting (possibly contrary to the fact) the
chemotherapy variable to “no chemotherapy” in Eq. (1). Second, to
test whether chemotherapy effects differed between patients with
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Table  1
Multivariable prediction models for 5-month and 1-year mortality risk in canines surgically treated for osteosarcoma.
Variables Regression coefﬁcients at 5 months Regression coefﬁcients at 1 year
Intercept ˆˇ 0 = −1.2379 ˆ0 = −0.4634
Chemotherapy
No chemotherapy ˆˇ 1 = −0.0000 ˆ1 = 0.0000
Cisplatin ˆˇ 2 = −0.5108 ˆ2 = −0.1492
Lobaplatin, carboplatin ˆˇ 3 = −0.5276 ˆ3 = 0.0000
Doxorubicin ˆˇ 4 = −0.6539 ˆ4 = 0.0070
Doxorubicin combinations ˆˇ 5 = −0.9676 ˆ5 = −0.4326
Age (years) ˆˇ 6 = 0.0296 ˆ6 = 0.0173
Weight (kg) ˆˇ 7 = 0.0198 ˆ7 = 0.0127
Male  gender ˆˇ 8 = −0.2357 ˆ8 = 0.0740
Neutered ˆˇ 9 = −0.2357 ˆ9 = −0.1690
High SALP ˆˇ 10 = 0.3716 ˆ10 = 0.4603
Breed
Other breed ˆˇ 11 = −0.0000 ˆ11 = 0.0000
Rottweiler ˆˇ 12 = −0.1165 ˆ12 = 0.1648
Golden Retriever ˆˇ 13 = −0.1508 ˆ13 = 0.0591
Labrador Retriever ˆˇ 14 = −0.2107 ˆ14 = 0.0282x
Greyhound ˆˇ 15 = 0.2546 ˆ15 = −0.1241
Doberman ˆˇ 16 = 0.3853 ˆ16 = 0.4649
Mixed breed ˆˇ 17 = −0.3147 ˆ17 = −0.1687
Tumor location
Other ˆˇ 18 = 0.0000 ˆ18 = 0.0000
Prox. Humerus ˆˇ 19 = 0.4318 ˆ19 = 0.8687
Dist. Femur or Prox. Tibia ˆˇ 20 = −0.0305 ˆ20 = 0.2960
Dist. Radius ˆˇ 21 = −0.3711 ˆ21 = −0.2356
Example patient’s predicted logit(5-month mortality risk) = −1.2379 + 0.0000* no chemotherapy(0) + 0.0296*7.7
years + 0.0296*44 kg + −0.2357*female(0) + −0.2357* neutered (1) + 0.3716*high salp(1) + −0.0000*Other breed(0) + 0.0000*Other
location(0) = −0.0031
Example patient’s predicted 5-month mortality risk = 1/(1 + e−(−0.0031)) = 0.4992
Example patient’s logit(1 year mortality risk) = −0.4634 + 0.0000*no chemotherapy(0) + 0.0173*7.7
years + 0.0127*44 kg + 0.0740*female(0) + −0.1690* neutered (1) + 0.4603*high salp(1) + −0.0000*Other breed(0) + 0.0000*Other
location(0) = 0.5180
























rumbers represent natural logarithms of the odds ratios of 5 month or 1 year morta
ntervals. Results were adjusted for all other presented variables and a random int
roportional hazard models described in Schmidt et.al. (2013).
ifferent logit (mortality risks) a product term (i.e., the product of
he variables chemotherapy and logit (mortality risk)) was added
o a logistic regression model. This model regressed the mortality
ariable (5 months or 1 year) on chemotherapy, the logit (mortality
isk), the product term and the potential confounders: age, weight,
ex, neuter status, SALP, monocytes, lymphocytes, breed and tumor
ocation. Signiﬁcance of this product term was tested using a Wald
ased interaction test (Schmidt et al., 2014a). The chemotherapy
ffect for a patient with a speciﬁc logit(mortality risk) was calcu-
ated by adding the chemotherapy coefﬁcient to the interaction
erm coefﬁcient times the logit (mortality risk) (Schmidt et al.,
015).
To increase precision of the interaction effect, this was com-
ined with the estimate of the previous study (Schmidt et al., 2015).
esults were pooled using the inverse variance weighted estimator
nd between study heterogeneity was tested using the Q-statistic
Higgins and Thompson, 2002; Schmidt et al., 2014a)
.1.2. Data analysis: sensitivity analyses
To explore the robustness of our approach the following three
ensitivity analyses were performed:
Linearity of the continuous variables monocytes, lymphocytes,
ogit (mortality risk) and the chemotherapy by logit (mortality
isk) with the outcome at 5 months and 1 year was  assessed using
estricted cubic splines with 5 knots (Harrell, 2001). No signiﬁcantease see Tables 3 and 4 for the model coefﬁcient as odds ratio’s with 95% conﬁdence
t for study. These multivariable logistic regression models are variation of the cox
deviations form linearity could be found. Additionally, graphically
exploring linearity showed that there was  some deviation for the
monocytes and lymphocytes (showing a slight sinus pattern) how-
ever, these could be approximated by a linear term. Previously,
the linearity of age, weight and SALP was assessed using the same
approach (Schmidt et al., 2013). In this analysis, SALP was  observed
to be non-linearly related with the outcome, because of this non-
linear relationship SALP was dichotomized.
As described above, we explored external performance of our
“original” prediction models for 5-month and 1-year mortality
risk, without and with updating the intercept. As previously indi-
cated (Schmidt et al., 2013), however, performance could perhaps
be improved by adding more variables or recoding variables. To
explore this we  added the variables monocytes and lymphocytes
to the model in “Update 2”. Additionally, to compare performance
of our “original” model to a model optimally tailored to the cur-
rent dataset we  re-estimate the entire model with addition of the
monocytes variable and a recoded breed variable (mixed breed,
giant purebred, large purebred and medium purebred) in “Update
3”. Finally, to determine if reducing the model might improve per-
formance, we performed a backward selection procedure using
a P-value criterion of 0.30 (“Update”). To correct for model opti-
mism,  model performance metrics for updates 1–4 were calculated
in 200 bootstrap samples (Harrell et al., 1996; Steyerberg, 2009;
Steyerberg et al., 2010). Model performance of updates 2–4 was






















































Fig. 1. Calibration plot comparing predicted probabilities to observed probabilities.
Perfect calibration is indicated by the solid diagonal line. The dotted line indicates
the non-parametric line going through the decile speciﬁc estimates (triangles). TheA.F. Schmidt et al. / Preventive Ve
ery similar to the performance of Update 1 and the external vali-
ation (see Appendix Tables 1–3).
In the current cohort study chemotherapy was not allocated
andomly. Thus it is likely that dogs receiving chemotherapy had
 better prognosis than dog not receiving chemotherapy, which
ould bias our results. Besides adjusting for measured confounders
s described above, we explored this further by repeating all analy-
es regarding the chemotherapy by logit (mortality risk) interaction
xcluding patients dying in the ﬁrst 30 days (a similar analysis was
onducted in Schmidt et al. (2015)), excluding 23% and 9% of the
ortality events at 5-month and 1-year. Results were very similar
nd are presented in Appendix Table 4.
All tests were applied using a signiﬁcance level of 0.05 (unless
tated otherwise), estimates are presented as odds ratios (OR) with
5% conﬁdence intervals (95% CI). Analyses were carried out using
he R statistical package for windows version 3.1.1 (R Development
ore Team, 2013).
. Results
Baseline characteristics are presented in Table 2. The median
ollow-up time was 241 days with 50% of the follow-up being
etween 146 days and 472 days. During follow-up 163 dogs did
ot receive any chemotherapy, 172 received carboplatin, 238 dox-
rubicin and for 221 patients the chemotherapy regime received
as not recorded. Except for higher SALP levels, dogs not receiv-
ng chemotherapy were similar to dogs receiving carboplatin or
oxorubicin therapy.
.1. Results:prediction model validation
The external validation of the original prediction model for 5
onths without any updating showed a slightly better c-statistic
han in the original derivation data (0.67 95% CI 0.61; 0.72), Table 3.
he calibration slope (1.15 95% CI 0.77; 1.52) and the calibration-
n-the-large (−0.1050 95% CI-0.29; 0.08) indicated that there was
light model misspeciﬁcation in tail areas and that the model sys-
ematically overestimated the risk (Fig. 1). Updating the intercept
orrected the systematic overestimation; calibration-in-the-large
−0.0004 95% CI-0.16; 0.16).
At 1 year the c-statistic (Table 4) was 0.62 (95% CI 0.58; 0.66),
ndicating that it was difﬁcult to discriminate between patient
xperiencing an event and those, which remained event free. While
he model misspeciﬁcation in the tail areas was  small (calibration
lope: 0.95 95% CI 0.63; 1.28), there was considerable underesti-
ation, indicated by a calibration-in-the-large of 0.2519 (95% CI
.10; 0.40). Updating the intercept resulted in an almost perfect
alibrated model (Fig. 1).
.2. Results: chemotherapy by mortality risk
Given the good performance of the original models we  esti-
ated the logit(mortality risk) under no chemotherapy treatment.
he median and range logit(mortality risk) under no chemotherapy
ere: −0.60 (−1.75; 0.85) for 5 months and 0.26 (−0.72; 2.14) for 1
ear. Transformed to the risk scale this becomes: 0.35 (0.15; 0.70)
nd 0.56 (0.33, 0.90).
For a patient with a 0.50 predicted risk of dying at 5 months [i.e.,
 logit (5-month mortality) of 0.00] the effect of “any chemother-
py” compared to no chemotherapy on preventing mortality was
R 0.45 (95% 0.25; 0.81; Table 5). The interaction effect showed
here was considerable difference between patients with a dif-
erent mortality risk: OR 1.89 (95% CI 0.83; 4.33). To get a more
recise estimate results were pooled with those from Schmidt et al.
2015), resulting in an interaction effect OR 2.31 (95% CI 1.18; 4.53;
able 5). While there was considerable difference in effectivenesssolid curve indicates the smoothed polynomial loess curve between the predicted
risk and the event indicator. The spike histogram indicates the frequencies of the
predicted risk.
in the current population, the majority of patients beneﬁtted from
chemotherapy (Fig. 2).
For a patient with a 0.50 risk of 1-year mortality, chemother-
apy was slightly less effective in preventing mortality OR 0.57 (95%
CI 0.35; 0.91; Table 5). Furthermore, the interaction effect OR of
1.26 (95% CI 0.60; 2.63) was  closer to the 1.00 indicating a smaller
difference in effectiveness. Combining results with those from the
previous study (Schmidt et al., 2015) resulted in a non-signiﬁcant
interaction effect: OR 1.39 (95 CI% 0.76; 2.54; Table 5). Fig. 2, indeed
shows a small difference in chemotherapy effectiveness. This indi-
cates that perhaps the interaction effect is redundant. Excluding the
interaction effect resulted in a chemotherapy effect that was equal
for all patients regardless of their predicted risk: OR 0.60 (95% CI
0.39; 0.92).
Overall, the effects of any chemotherapy against no chemother-
apy were comparable to the effects of carboplatin or doxorubicin
against no chemotherapy (Table 5). The heterogeneity between
the current study and the results from (Schmidt et al., 2015) were
non-signiﬁcant (available upon request).
4. Discussion
In this study, we  described the external validation of two mul-
tivariable models predicting 5-month and 1-year mortality risk
in dogs surgically treated for osteosarcoma (OS). Additionally, we
reproduced a previously reported chemotherapy by predicted risk
interaction effect, indicating that a dog’s predicted risk of mortality
modiﬁes the effectiveness of chemotherapy.
Results showed that both prediction models (for 5-month and
1-year mortality risk) generalized well to the current independent
dataset. For the 1-year mortality prediction model recalibration of
the intercept (Update 1) was needed to correct for differences in
mortality incidence. This recalibration is common when applying a
prediction model to a new setting and can easily be implemented in
clinical practice using the R code provided in Appendix A of Supple-
mentary material. Compared to the previous publication (Schmidt
130 A.F. Schmidt et al. / Preventive Veterinary Medicine 125 (2016) 126–134
Table  2
Baseline characteristics of 794 canines surgically treated for osteosarcoma stratiﬁed by treatment status.
Variables No chemotherapy Carboplatin Doxorubicin Number of missings
N  = 163 N = 172 N = 238 N = 221
Follow up in days median(Q1; Q3) 145.00 (35.00;539.25) 256.00 (166.00;539.25) 269.00 (165.75;539.25)
5  month mortality N (%) 75 (49%) 30 (18%) 46 (20%) 23
1  year mortality N (%) 116 (79%) 93 (62%) 138 (59%) 48
Age  (years) mean (sd) 8.80 (2.82) 7.96 (2.52) 8.56 (2.41) 1
Weight  (kg) mean (sd) 41.42 (13.47) 42.87 (14.38) 39.84 (11.51) 1
Male  gender N (%) 86 (53%) 100 (58%) 129 (54%) 0
Neutered N (%) 149 (91%) 158 (92%) 227 (95%) 0
High  SALP N (%) 60 (42%) 45 (30%) 64 (28%) 76
Monocytes (109/L) median (Q1; Q3) 0.50 (0.30; 0.80) 0.40 (0.30; 0.80) 0.50 (0.30; 0.80) 149
Lymphocytes (109/L) median (Q1; Q3) 1.30 (0.80; 1.70) 1.25 (0.92; 1.70) 1.20 (0.90; 1.70) 150
Breed
Other  breed N(%) 52 (32%) 73 (42%) 60 (25%) 0
Rottweiler N (%) 25 (15%) 20 (12%) 40 (17%)
Golden Retriever N (%) 16 (10%) 15 (9%) 28 (12%)
Labrador Retriever N (%) 17 (10%) 31 (18%) 29 (12%)
Greyhound N (%) 4 (2%) 5 (3%) 15 (6%)
Doberman N (%) 9 (6%) 8 (5%) 8 (3%)
Mixed breed N (%) 40 (25%) 20 (12%) 58 (24%)
Tumor  location 11
Other N (%) 42 (26%) 44 (26%) 60 (26%)
Prox.  Humerus N (%) 24 (15%) 29 (17%) 48 (21%)
Dist.  Femur or Prox. Tibia N (%) 66 (41%) 69 (40%) 66 (28%)
Dist.  Radius N (%) 29 (18%) 29 (17%) 59 (25%)
Serum alkaline phosphatase (SALP); N equals the number of subjects, sd equals the standard deviation, Q1 indicates quartile 1, Q3 indicates quartile 3.
Table 3
External validation and updating of a multivariable model predicting 5-month mortality in canines surgically treated for osteosarcomaa.
Variables Original model External validation Update 1
Odds ratio ˆˇ Odds ratio ˆˇ Odds ratio ˆˇ
Calibration slope 0.77 (0.55;1.00) 1.15 (0.77;1.52) 1.15 (0.77;1.52)
Calibration in the large −0.0005 (−0.13;0.13) −.1050 (−0.29;0.08) −.0004 (−0.16;0.16)
AUC  (c-statistic)b 0.63 (0.59;0.67) 0.67 (0.61;0.72) 0.67 (0.61;0.72)
Intercept −1.2379 −1.3429
Chemotherapy
No chemotherapy Reference 0.0000
Cisplatin 0.60 (0.31;1.15) −0.5108
Carboplatin 0.59 (0.32;1.10) −0.5276
Doxorubicin 0.52 (0.29;0.95) −0.6539
Doxorubicin combinations 0.38 (0.21;0.68) −0.9676
Age  (years) 1.03 (0.97;1.09) 0.0296
Weight (kg) 1.02 (1.00;1.03) 0.0198
Male gender 0.79 (0.60;1.05) −0.2357
Neutered 0.79 (0.54;1.15) −0.2357
High SALP 1.45 (1.08;1.95) 0.3716
Breed
Other breed Reference 0.0000
Rottweiler 0.89 (0.58;1.35) −0.1165
Golden retriever 0.86 (0.53;1.39) −0.1508
Labrador retriever 0.81 (0.48;1.37) −0.2107
Greyhound 1.29 (0.70;2.37) 0.2546
Doberman 1.47 (0.81;2.69) 0.3853
Mixed breed 0.73 (0.49;1.09) −0.3147
Tumor location
Other Reference 0.0000
Prox. humerus 1.54 (1.05;2.25) 0.4318
Dist. femur or prox. tibia 0.97 (0.65;1.44) −0.0305
Dist. radius 0.69 (0.46;1.04) −0.3711
a In the external validation the original model was applied to an independent dataset without re-estimating any coefﬁcients. In update 1 the original model was again
applied to the same independent dataset only now with a re-estimated intercept coefﬁcient. In the original publication lobaplatin and carboplatin where combined, in this




with 95% conﬁdence intervals in brackets.





and  predicted risk on the logit scale and measures any systematic over- or underes
b The c-statistics is the proportion of subjects that experienced an event and that 




it is not actually on the natural logaritht al., 2013) (original model in Tables 3 and 4), the discriminative
bility (c-statistic between 0.62; 0.67) of both models was  similaron.
ed a higher predicted risk than subjects that did not experience an event. Also note
ale but is a regular proportion bounded by 0 and 1.but modest. This indicates that the models have difﬁculty discrim-
inating between subjects experiencing an event and those that did
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Table  4
External validation and updating of a multivariable model predicting 1-year mortality in canines surgically treated for osteosarcomaa.
Variables Original model External validation Update 1
Odds ratio ˆ Odds ratio ˆ Odds ratio ˆ
Calibration slope 0.82 (0.61;1.02) 0.95 (0.63;1.28) 0.95 (0.63;1.28)
Calibration in the large −.0002 (−0.12;0.12) 0.2519 (0.10;0.40) −.0019 (−0.15;0.15)
AUC  (c-statistic)b 0.64 (0.60;0.67) 0.62 (0.58;0.66) 0.62 (0.58;0.66)
Intercept −0.4634 −0.2114
Chemotherapy
No chemotherapy Reference 0.0000
Cisplatin 0.86 (0.45;1.64) −0.1492
Carboplatin 1.00 (0.55;1.84) 0.0000
Doxorubicin 1.01 (0.56;1.81) 0.0070
Doxorubicin combinations 0.65 (0.37;1.14) −0.4326
Age (years) 1.02 (0.97;1.07) 0.0173
Weight (kg) 1.01 (1.00;1.02) 0.0127
Male gender 1.08 (0.83;1.39) 0.0740
Neutered 0.84 (0.59;1.21) −0.1690
High SALP 1.58 (1.19;2.11) 0.4603
Breed
Other breed Reference 0.0000
Rottweiler 1.18 (0.78;1.77) 0.1648
Golden Retriever 1.06 (0.69;1.63) 0.0591
Labrador Retriever 1.03 (0.64;1.66) 0.0282
Greyhound 0.88 (0.50;1.56) −0.1241
Doberman 1.59 (0.85;2.97) 0.4649
Mixed breed 0.84 (0.60;1.19) −0.1687
Tumor location
Other Reference 0.0000
Prox. Humerus 2.38 (1.64;3.46) 0.8687
Dist. Femur or Prox. Tibia 1.34 (0.95;1.91) 0.2960
Dist. Radius 0.79 (0.56;1.12) −0.2356
a In the external validation the original model was  applied to an independent dataset without re-estimating any coefﬁcients. In update 1 the original model was again
applied  to the same independent dataset only now with a re-estimated intercept coefﬁcient. In the original publication lobaplatin and carboplatin where combined, in this




with 95% conﬁdence intervals in brackets.
The  calibration slope measures how well observed and predicted risk correlates in the tails and is ideally 1. Calibration-in-the large is the mean difference between observed
and  predicted risk on the logit scale and measures any systematic over- or underestimation.
b The c-statistics is the proportion of subjects that experienced an event and that received a higher predicted risk than subjects that did not experience an event. Also note




it is not actually on the natural logarithmic scale but is a regular proportion bounded by 0 and 1
Table 5
Treatment effect modiﬁcation of adjuvant chemotherapy by predicted risk on 5-month and 1-year mortality incidence in canines surgically treated for osteosarcoma.
Any chemotherapy Carboplatin Doxorubicin
5 month mortality
Original discovery
Main treatment effect 0.81 (0.41; 1.62) 0.73 (0.12; 4.53) 0.74 (0.26; 2.09)
Interaction effect 3.41 (1.07; 10.84) 4.06 (0.28; 59.07) 6.46 (0.89; 46.66)
External  validation
Main treatment effect 0.45 (0.25; 0.81) 0.49 (0.23; 1.07) 0.42 (0.22; 0.81)
Interaction effect 1.89 (0.83; 4.33) 2.25 (0.68; 6.98) 1.74 (0.67; 4.55)
Pooled  estimates
Main treatment effec 0.58 (0.37; 0.90) 0.52 (0.26; 1.06) 0.49 (0.28; 0.86)
Interaction effect 2.31 (1.18; 4.53) 2.41 (0.83; 6.99) 2.23 (0.94; 5.30)
1year  mortality
Original discovery
Main treatment effect 0.56 (0.28; 1.10) 0.85 (0.30; 2.38) 0.58 (0.19; 1.74)
Interaction effect 1.71 (0.60; 4.89) 0.48 (0.09; 2.49) 2.50 (0.53; 11.92)
External validation
Main treatment effect 0.57 (0.35; 0.91) 0.68 (0.38; 1.23) 0.49 (0.30; 0.82)
Interaction effect 1.26 (0.60; 2.63) 1.19 (0.46; 3.06) 1.31 (0.58; 2.98)
Pooled  estimates
Main treatment effect 0.56 (0.38; 0.83) 0.72 (0.43; 1.20) 0.51 (0.80; 0.32)
Interaction effect 1.39 (0.76; 2.54) 0.95 (0.42; 2.15) 1.51 (0.73; 3.11)
Results presented as odds ratios (95% conﬁdence intervals) with no chemotherapy as the reference group. The interaction effect describes by how much the treatment effect






aocation, monocytes and lymphocytes; no model selection was  performed. The origi
alidation refers to the current study, the pooled estimates were derived using a ﬁxe
measured by the Q-statistic).ot. In part, this was caused by the fact that most patients had a
imilar risk. The good calibration (agreement between observed
nd predicted risk) indicates that the clustering of risk is a charac-covery refers to results from the discovery study (Schmidt et al., 2015), the external
cts inverse variance pooling; there was no signiﬁcant between study heterogeneityteristic of the patient population, not a modelling error. Given the
modest discriminative ability but good calibration, these risk pre-
diction models are perhaps best used for identifying patients at a
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igure  shows the odds ratio (OR) of any chemotherapy treatment (solid line) with 9
ortality. The horizontal solid line indicates a neutral OR of 1.00. At the bottom a spik
igh- or low risk of mortality, not for indicating which patient will
ctually die.
The chemotherapy by predicted risk (strictly speaking the
ogit of the predicted risk) interaction showed that chemother-
py was more effective in preventing 5-month mortality in lower
isk patients (risk cut off 0.52). Our ﬁndings imply that short
erm (i.e., 5 months) effectiveness of chemotherapy depends on
 dogs predicted risk of 5-month mortality. Contrary to our pre-
ious study (Schmidt et al., 2015), most patients beneﬁtted from
dditional chemotherapy. This difference in overall chemotherapy
ffectiveness was caused by a lower baseline risk in this popula-
ion compared to the previous study. This also demonstrates that
n the presence of a chemotherapy interaction (for 5-month mor-
ality) the overall average effect estimate is inappropriate, instead
n individualized chemotherapy effect estimate should be used
Schmidt et al., 2014b). Due to this interaction a different frac-
ion of patients will beneﬁt from chemotherapy depending on the
opulation speciﬁc predicted risk distribution. If every dog in a
articular population beneﬁts from chemotherapy (e.g., because
he entire population consists of low risk patients), individualiz-
ng treatments becomes less important. Potentially, however, in
 setting where each dog beneﬁts, difference in chemotherapy
ffectiveness may  still be of interest from a health economic per-
pective. At 1 year, we did not ﬁnd an interaction (similar to the
revious study, Schmidt et al., 2015), however, due to the wide con-
dence interval around the interaction effect, we  cannot exclude
hat such an interaction does exist (Schmidt et al., 2016). Based on
he current evidence it seems most appropriate, however, to use
he main effect of chemotherapy compared to no chemotherapy,
stimated in a model without an interaction, of OR 0.60 (95% CI
.39; 0.92) for all patients regardless of their predicted risk. Finally,
s in the discovery paper (Schmidt et al., 2015), we recognize that
he above described interaction tests ignore the uncertainty in the
redicted logit (mortality), underestimating the variance. To adjustnﬁdence intervals (dotted lines) for dogs with different predicted risks of 5-month
ogram is given, corresponding to the patient frequencies of the x-axis measurement.
for this, following the same approach as in our previous paper
(Schmidt et al., 2015), we bootstrapped the original dataset reﬁt-
ting the prediction model (2000 bootstrap sample per imputed
dataset), re-estimating the predicted risk and the interaction effect.
Unexpectedly this led to smaller conﬁdence intervals than when
ignoring the ﬁrst stage uncertainty: interaction OR  1.89 (95% CI
1.20; 2.97) and OR 1.26 (95% CI 0.98; 1.63), for 5 months and 1-
year mortality. Possibly this decrease in variance is related to the
fact that bootstrapping the original prediction models increases
its external performance (i.e., ﬁts external data better), decreasing
differences between observed and predicted risk (Harrell, 2001).
However, as shown above, at least for the 5-months prediction
model, the predicted risk already ﬁtted the observed risk reason-
ably well. Clearly, this issue of how to incorporate the ﬁrst stage
uncertainty needs further theoretical consideration.
Our ﬁnding that chemotherapy effectiveness depends on a
second variable has also been shown in other studies. An exam-
ple would be the synergistic effect between immunotherapy and
chemotherapy (MacEwen and Kurzman, 1996; Vail et al., 1995). To
the best of our knowledge, we are the ﬁrst to show that chemother-
apy effectiveness may  depend on multiple variables.
The current study has some important limitations. First, in the
current cohort study chemotherapy was not randomly allocated.
While results were adjusted for potential confounding, it seems
likely that there is still remaining bias due to residual or unobserved
confounding. For example, decisions on euthanasia may  partially
dependent on the type of chemotherapy prescribed (e.g., due to dif-
ferences in side effects), and almost certainly on the decision to not
use further chemotherapy. Instead of focussing on all-cause mor-
tality (as done here), one might be tempted to focus on “naturally”
occurring death and censor (using a survival model) or disregard
(using logistic regression) dogs who were euthanized. However,
confounding bias would likely remain and even in its absence this
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004), an issue we addressed in Schmidt et al. (2013). On the other
and, because the decisions around chemotherapy may  not only
epends on a patients’ life expectancy but also on an owner’s will-
ngness to pay, some degree of randomness might be expected.
evertheless, we expect there to be some degree of residual con-
ounding (by unmeasured variables affecting both chemotherapy
ecision and life expectancy Hernan and Robins, 2006) in the esti-
ates presented, and therefore, we hope that our ﬁndings might
ead to the initiation of new, or re-analysis of historical, randomized
linical trials (RCTs) further exploring the validity of our results.
Second, as reported, some observations were missing. Instead
f focusing on complete observation, which (by ignoring depen-
encies) leads to selection bias, missing values were imputed
Groenwold et al., 2012; White and Carlin, 2010). Third, no cor-
ection for multiple testing was applied. Given the modest amount
f tests and that similar ﬁndings were reported in a second inde-
endent study (Schmidt et al., 2015), we feel that such a correction
s redundant. Fourth, we emphasize that this is only a single vali-
ation study, based on a sample collected in a university hospital
n the USA, hence results may  differ from a primary care setting
n another region. Before implementing the prediction model in
 clinical setting, we suggest to validate the model anew, using
or example historical medical records and if need recalibrate the
odel using the code provided in Appendix A in Supplementary
aterial. Based on a recent publication from Collins et al. (2015)
t seems that such a validation study needs at the very least 100
vents to provide moderatly precise and unbiased estimates of
odel performance (i.e., calibration and discrimination).
Nevertheless, given the performance in this single external val-
dation study we would expected, even in settings where the
redicted risk does not agree with the the underlying true risk,
hat ranking of high- versus low risk patients will still be pos-
ible. Because of this we have included an excel spreadsheet to
id in calculating a patient’s risk of mortality (see Appendix A in
upplementary material). To reiterate, unless a local validation
tudy is performed, we would not expected the predicted risk
rom this spreadsheet program to match the true risks. There-
ore, we are hesitant to provide thresholds to categorize high-,
oderate- and low-risk patients, instead we  suggest practition-
rs use this tool to help rank patients to identify relatively high-
r low-risk patients (compared to the “average” patient encoun-
ers in their practice). After multiple validation studies, perhaps
 consensus could be reached on risk thresholds. For example, in
uman cardiovascular heart disease (CHD), risk threshold were
ecided by consensus in guideline groups based on information
n external validation of CHD prediction models [e.g., the Framing-
am (D’Agostino et al., 2008)], treatment efﬁcacy (e.g., statins) and
afety, and cost-effectiveness (Hingorani and Hemingway, 2011;
ingorani and Psaty, 2009). Due to the mentioned lack of random-
zation we have not included the interaction with chemotherapy in
he spreadsheet, we feel that this is best included after (historical)
CT data have conﬁrmed this interaction.
. Conclusions
Based on our results, we conclude that a dog’s risk of mortality,
fter surgical treatment for osteosarcoma, can be predicted using
he models presented. Dogs with a lower predicted risk of 5-month
ortality seem to beneﬁt most from additional chemotherapy.
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